Not Signed In -
Nose Disorders |
Nasal Disorders |
Clinical Trial: Reserpine for the Treatment of Cocaine Dependence - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to assess the efficacy and safety of reserpine for the treatment of cocaine dependence.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cocaine-Related Disorders Substance-Related Disorders | Drug: Reserpine | Phase II |
MedlinePlus related topics: Cocaine Abuse; Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence
Expected Total Enrollment: 140
Study start: July 2001; Study completion: May 2003
To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a 2 week baseline period.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking individuals; have the ability to understand and provide written informed consent; females of child bearing potential using appropriate birth control method
Exclusion Criteria:
Additional criteria available during screening at the site.
Location Information
Massachusetts
Boston University Medical Center, Boston, Massachusetts, 02215, United States
Ohio
Cincinnati VA Medical Center, Cincinnati, Ohio, 45220, United States
Dayton VA Medical Center, Dayton, Ohio, 45428, United States
Eugene Somoza, M.D., Ph.D., Principal Investigator, VA Medical Center-Cincinnati
More Information
Record last reviewed: August 2003
Last Updated: January 21, 2005
Record first received: April 5, 2002
ClinicalTrials.gov Identifier: NCT00033033
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
